These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23674603)

  • 1. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
    Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
    J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
    Andoh T; Yoshida T; Kuraishi Y
    Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
    Andoh T; Kuraishi Y
    J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
    Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
    Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
    Furue M; Kadono T; Tsuji G; Nakahara T
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
    Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
    Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
    Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
    J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
    Ohba F; Nomoto M; Hojo S; Akama H
    J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
    Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
    J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
    Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
    J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Application of a PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL-4 Production.
    Takahashi K; Miyake K; Ito J; Shimamura H; Suenaga T; Karasuyama H; Ohashi K
    J Invest Dermatol; 2024 May; 144(5):1048-1057.e8. PubMed ID: 37827277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
    Ishii N; Wakita H; Shirato M
    J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
    J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
    Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A
    J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
    Ahluwalia J; Udkoff J; Waldman A; Borok J; Eichenfield LF
    Drugs; 2017 Sep; 77(13):1389-1397. PubMed ID: 28681318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
    Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
    Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
    Harada D; Takada C; Nosaka Y; Takashima Y; Kobayashi K; Takaba K; Manabe H
    Int Immunopharmacol; 2009 Jan; 9(1):55-62. PubMed ID: 18854230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
    Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of topically applied Korean red ginseng and its genuine constituents on atopic dermatitis-like skin lesions in NC/Nga mice.
    Kim HS; Kim DH; Kim BK; Yoon SK; Kim MH; Lee JY; Kim HO; Park YM
    Int Immunopharmacol; 2011 Feb; 11(2):280-5. PubMed ID: 21118672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.